Celon Pharma Balance Sheet Health

Financial Health criteria checks 6/6

Celon Pharma has a total shareholder equity of PLN459.4M and total debt of PLN0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are PLN576.3M and PLN117.0M respectively.

Key information

0%

Debt to equity ratio

zł0

Debt

Interest coverage ration/a
Cashzł121.09m
Equityzł459.37m
Total liabilitieszł116.96m
Total assetszł576.33m

Recent financial health updates

Recent updates

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Aug 21
A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24
Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Jul 13
Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Nov 04
We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Aug 04
We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

May 23
Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Mar 02
Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Feb 09
Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Jan 20
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Dec 24
Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Dec 03
Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Financial Position Analysis

Short Term Liabilities: CLN's short term assets (PLN206.7M) exceed its short term liabilities (PLN79.3M).

Long Term Liabilities: CLN's short term assets (PLN206.7M) exceed its long term liabilities (PLN37.7M).


Debt to Equity History and Analysis

Debt Level: CLN is debt free.

Reducing Debt: CLN had no debt 5 years ago.

Debt Coverage: CLN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CLN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies